
Orasis Pharmaceuticals seeks Australian approval for presbyopia eye drop
Orasis Pharmaceuticals has reached a regulatory milestone by submitting a New Drug Application to Australia’s Therapeutic Goods Administration for its pilocarpine-based eye drop, branded as BESKA. The move marks the first international expansion for the treatment, which is already marketed as QLOSI in the United States.


























